BAY41-4109 Racemic CAS NO.298708-79-9

bay 41-4109 is able to both accelerate and misdirect capsid assembly in vitro. preformed capsids are stabilized by bay 41-4109, up to a ratio of one inhibitor molecule per two dimers^[2]. bay 41-4109 is equally effective at inhibiting hbv dna release and the cytoplasmic hbcag level, with ic₅₀s of 32.6 and 132 nm in hepg2.2.15 cells, respectively. hbv dna and hbcag are inhibited in a dose-dependent manner, indicating that the anti-hbv mechanisms are associated with and dependent on the rate of hbcag inhibition^[3].

[1]. weber o, et al. inhibition of human hepatitis b virus (hbv) by a novel non-nucleosidic compound in a transgenic mouse model. antiviral res. 2002 may;54(2):69-78.

[2]. stray sj, et al. bay 41-4109 has multiple effects on hepatitis b virus capsid assembly. j mol recognit. 2006 nov-dec;19(6):542-8.

[3]. wu gy, et al. inhibition of hepatitis b virus replication by bay 41-4109 and its association with nucleocapsid disassembly. j chemother. 2008 aug;20(4):458-67.

tianjin kailiqi biopharma technology co., ltd, is a professional manufacturer specialized in the production and distribution of active pharmaceutical ingredients and intermediates. our company has strong r&d ability and production experience to provide the customers new apis. we specialize in developing innovative processes for the synthesis of a wide range of products. we also undertake custom synthesis and contract manufacturing.if you are interest in,pls contact with me,we also have lab,specifical in some hard synthesis.